CN114796236A - 用于治疗痴呆的组合物 - Google Patents

用于治疗痴呆的组合物 Download PDF

Info

Publication number
CN114796236A
CN114796236A CN202210417996.0A CN202210417996A CN114796236A CN 114796236 A CN114796236 A CN 114796236A CN 202210417996 A CN202210417996 A CN 202210417996A CN 114796236 A CN114796236 A CN 114796236A
Authority
CN
China
Prior art keywords
estradiol
acid
dementia
composition
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210417996.0A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·霍夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN114796236A publication Critical patent/CN114796236A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202210417996.0A 2016-09-12 2017-09-08 用于治疗痴呆的组合物 Pending CN114796236A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662393140P 2016-09-12 2016-09-12
US62/393,140 2016-09-12
US201762507531P 2017-05-17 2017-05-17
US62/507,531 2017-05-17
CN201780055706.XA CN110177572A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物
PCT/US2017/050653 WO2018049141A1 (en) 2016-09-12 2017-09-08 Compositions for treating dementia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780055706.XA Division CN110177572A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物

Publications (1)

Publication Number Publication Date
CN114796236A true CN114796236A (zh) 2022-07-29

Family

ID=59901615

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780055706.XA Pending CN110177572A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物
CN202210417996.0A Pending CN114796236A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780055706.XA Pending CN110177572A (zh) 2016-09-12 2017-09-08 用于治疗痴呆的组合物

Country Status (12)

Country Link
US (1) US10300077B2 (enExample)
EP (1) EP3509639A1 (enExample)
JP (1) JP2019526612A (enExample)
KR (1) KR20190072521A (enExample)
CN (2) CN110177572A (enExample)
AU (1) AU2017322332A1 (enExample)
BR (1) BR112019004540A2 (enExample)
CA (1) CA3036511A1 (enExample)
IL (1) IL265255A (enExample)
MX (1) MX2019002673A (enExample)
PH (1) PH12019500479A1 (enExample)
WO (1) WO2018049141A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
JP2022532210A (ja) 2019-05-14 2022-07-13 タイム，インコーポレーテッド がんを処置する組成物および方法
US10905698B1 (en) * 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
CN1429556A (zh) * 2001-12-18 2003-07-16 有限会社大长企画 强肌肉剂和抗炎症剂
US20030157199A1 (en) * 2001-07-31 2003-08-21 Daicho Kikaku Incorporated Company Health food products
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
CN101296691A (zh) * 2005-08-05 2008-10-29 努沃研究公司 透皮释药剂型
US20090123571A1 (en) * 2005-03-25 2009-05-14 Alan Meehan Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
CN102448306A (zh) * 2009-04-09 2012-05-09 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性紊乱的方法
US20140288030A1 (en) * 2013-03-24 2014-09-25 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161442A (ja) * 1989-11-21 1991-07-11 Chiyouseidou Seiyaku Kk コール酸又はそのナトリウム塩からなる脳代謝改善剤
JPH06100466A (ja) * 1992-02-14 1994-04-12 Tsumura & Co ストレス性脳神経細胞器質障害防御剤
US5733926A (en) 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
CA2585471A1 (en) * 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
AU2006294662A1 (en) * 2005-09-26 2007-04-05 The Regents Of The University Of California Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
WO2008016768A1 (en) * 2006-08-02 2008-02-07 Roberta Diaz Brinton Phytoestrogenic formulations and uses thereof
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
CA2911547A1 (en) * 2013-05-31 2014-12-04 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US20030157199A1 (en) * 2001-07-31 2003-08-21 Daicho Kikaku Incorporated Company Health food products
CN1429556A (zh) * 2001-12-18 2003-07-16 有限会社大长企画 强肌肉剂和抗炎症剂
US20090123571A1 (en) * 2005-03-25 2009-05-14 Alan Meehan Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
CN101296691A (zh) * 2005-08-05 2008-10-29 努沃研究公司 透皮释药剂型
CN102448306A (zh) * 2009-04-09 2012-05-09 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性紊乱的方法
US20140288030A1 (en) * 2013-03-24 2014-09-25 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOWARD FILLIT等: "Observations in a preliminary open trial of estradiol therapy for senile dementia-alzheimer\'s type", PSYCHONEUROENDOCRINOLOGY, vol. 11, no. 3, 1 January 1986 (1986-01-01), pages 337, XP024386894, DOI: 10.1016/0306-4530(86)90019-3 *

Also Published As

Publication number Publication date
WO2018049141A1 (en) 2018-03-15
AU2017322332A1 (en) 2019-04-04
CN110177572A (zh) 2019-08-27
CA3036511A1 (en) 2018-03-15
PH12019500479A1 (en) 2019-07-29
BR112019004540A2 (pt) 2019-05-28
US20180071316A1 (en) 2018-03-15
JP2019526612A (ja) 2019-09-19
WO2018049141A4 (en) 2018-05-03
KR20190072521A (ko) 2019-06-25
IL265255A (en) 2019-05-30
EP3509639A1 (en) 2019-07-17
US10300077B2 (en) 2019-05-28
MX2019002673A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
JP5289281B2 (ja) Ｃｎｓ疾患の治療において使用するためのプレグナンステロイド
Traish et al. Dehydroepiandrosterone (DHEA)—a precursor steroid or an active hormone in human physiology (CME)
US12415829B2 (en) Progesterone phosphate analogs and uses related thereto
JP2001510471A (ja) アンドロゲン合成インヒビター
US12459970B2 (en) Progesterone analogs and uses related thereto
CN114796236A (zh) 用于治疗痴呆的组合物
JP2016527307A5 (enExample)
AU2006229840B2 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
Huang et al. From dried bear bile to molecular investigation of differential effects of bile acids in ex vivo and in vitro models of myocardial dysfunction: Relevance for neuroinflammation
Fedotcheva et al. Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application
JP2019526612A5 (enExample)
EP2687215B1 (en) Mesterolone pharmaceutical composition for dihydrotestosterone deficiencies in woman
ES2423493T3 (es) Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC
EP4429669A1 (en) Steroid as a modulator of gabaa receptor
Anita et al. Use of Progestogens in Clinical Practice of Obstetrics and Gynecology
TW201402126A (zh) 用於治療子宮內膜異位症之固醇硫酸酯酶抑制劑之組合
GENAZZANI et al. methods, techniques, drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220729

WD01 Invention patent application deemed withdrawn after publication